MedsWatch is an informal group of academic researchers and others interested in using data to reduce the risk of people being exposed to poor quality medicines. It’s also the name we’ve given to a system that aims to use market and other information to predict which medicines are at particularly high risk for being fake (falsified medicine), and which are most likely to have been badly made or to have degraded, so that when they reach the patient they don’t work the way they should (substandard medicine).
This blog is a repository for some of our thoughts and observations, as well as a place to share data, news stories and ideas related to medicine quality. We welcome contributions from other researcher, regulators, or colleagues past, present or future.
Read more about the MedsWatch Team.
You can email us through the contact form, or reach us on Twitter @MedsWatch.
Latest from the Blog
Quality-by-association? The knock-on effect of sloppy regulation in rich countries
With COVID-19 diagnostics, “stringent regulatory authorities” are anything but stringent. Opportunistic companies (and DJs) profit, while poorer countries are hoodwinked.
Journal Club: The tricky business of research on medicine quality
Hodges and Garnett describe the tricks academics use to tell stories about fake medicines, though evidence is slim. (They use all the same tricks in their own paper.)
Indonesia, USA: medicine pricing causes common headaches
The US and Indonesia are very different, but medicine reimbursement policies in both countries sometimes encourage pharmacies to limit stocks of cheaper drugs
Get new content delivered directly to your inbox.
